Filing Details

Accession Number:
0001209191-20-058567
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-11-16 19:37:24
Reporting Period:
2020-11-12
Accepted Time:
2020-11-16 19:37:24
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1679363 Morphic Holding Inc. MORF Pharmaceutical Preparations (2834) 473878772
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1780270 William Devaul C/O Morphic Holding, Inc.
35 Gatehouse Drive, A2
Waltham MA 02451
General Counsel And Secretary No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-11-12 390 $4.32 3,676 No 4 M Direct
Common Stock Disposition 2020-11-12 390 $30.00 3,286 No 4 S Direct
Common Stock Acquisiton 2020-11-13 530 $4.32 3,816 No 4 M Direct
Common Stock Disposition 2020-11-13 530 $30.00 3,286 No 4 S Direct
Common Stock Acquisiton 2020-11-16 500 $4.32 3,786 No 4 M Direct
Common Stock Disposition 2020-11-16 500 $30.05 3,286 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy Common Stock) Disposition 2020-11-12 390 $0.00 390 $4.32
Common Stock Stock Option (right to buy Common Stock) Disposition 2020-11-13 530 $0.00 530 $4.32
Common Stock Stock Option (right to buy Common Stock) Disposition 2020-11-16 500 $0.00 500 $4.32
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
179,159 2028-12-14 No 4 M Direct
178,629 2028-12-14 No 4 M Direct
178,129 2028-12-14 No 4 M Direct
Footnotes
  1. Includes 786 shares of Common Stock acquired under the issuer's employee stock purchase plan on August 31, 2020.
  2. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.14 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.10 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The option vests as to 2.0833% of the total shares monthly, beginning October 30, 2018, with 100% of the total shares vested and exercisable on September 30, 2022, subject to the reporting person's provision of service to the issuer on each vesting date.